NEW YORK, March 29, 2017 /PRNewswire/ --
Stock-Callers.com redirects investors' attention to the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry also includes the manufacturing and marketing of drugs as a result of direct research and development. Equities under assessment this morning are: Celsion Corp. (NASDAQ: CLSN), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Tenax Therapeutics Inc. (NASDAQ: TENX), and Cerulean Pharma Inc. (NASDAQ: CERU). You can access our complimentary research reports on these stocks now at:
Shares in Lawrenceville, New Jersey-based Celsion Corp. jumped 10.32%, ending Tuesday's trading session at $0.29. The stock recorded a trading volume of 3.93 million shares, which was higher than its three months average volume of 2.75 million shares. The Company's shares have surged 25.96% in the last month. The stock is trading 6.20% below its 50-day moving average. Moreover, shares of Celsion, which focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology, have a Relative Strength Index (RSI) of 52.30.
On March 16th, 2017, Celsion announced financial results for the year ended December 31st, 2016, and provided an update on its development programs for ThermoDox®. The Company reported a net loss of $22.1 million for the year, R&D costs of $14.6 million, and total operating expenses of $21.2 million. Visit us today and download your complete report on CLSN for free at:
New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.'s stock declined 2.57%, closing the day at $3.79 with a total trading volume of 920,943 shares. The Company's shares are trading 8.13% below their 50-day moving average. Shares of the Company, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have an RSI of 41.80.
On March 21st, 2017, Achillion Pharmaceuticals announced that the US Patent and Trademark Office (USPTO) has issued the first US Patent to the Company resulting from its complement factor D research program. The USPTO has also issued Notices of Allowance of four additional US patent applications owned by Achillion, also with claims to compositions of matter, that are expected to issue as patents over the next few months. The complimentary research report on ACHN can be accessed at:
On Tuesday, shares in Morrisville, North Carolina headquartered Tenax Therapeutics Inc. recorded a trading volume of 278,244 shares. The stock ended the day 3.90% lower at $0.49. The Company's shares are trading below their 50-day moving average by 51.45%. Furthermore, shares of Tenax Therapeutics, which focuses on the development and commercialization of a portfolio of products for the critical care market in the US and Canada, have an RSI of 22.04.
On March 21st, 2017, Tenax Therapeutics announced financial results for the full year ended December 31st, 2016, and provided a corporate update. The Company reported a net loss of $44.0 million for the year, general and administrative expenses of $6.2 million, R&D expenses of $13.1 million, and a loss on impairment of assets of $33.3 million. Register for free on Stock-Callers.com and download the PDF research report on TENX at:
Waltham, Massachusetts-based Cerulean Pharma Inc.'s stock jumped 5.07%, finishing yesterday's session at $0.73 with a total trading volume of 3.76 million shares. The Company's shares have advanced 2.37% on an YTD basis. The stock is trading below its 50-day moving average by 44.03%. Additionally, shares of Cerulean Pharma, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, have an RSI of 39.29. Get free access to your research report on CERU at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA